MATTHEW M. WALSH - 29 Mar 2024 Form 4 Insider Report for Organon & Co. (OGN)

Role
Chief Financial Officer
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh
Issuer symbol
OGN
Transactions as of
29 Mar 2024
Transactions value $
$0
Form type
4
Filing time
02 Apr 2024, 16:12:04 UTC
Previous filing
01 Mar 2024
Next filing
03 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Award $0 +45.2K $0.00 45.2K 29 Mar 2024 Common Stock 45.2K Direct F1, F2
transaction OGN Stock Option (right to buy) Award $0 +185K $0.00 185K 29 Mar 2024 Common Stock 185K $18.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.
F2 These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
F3 The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.